Check out our posters at the American Association for Cancer Research 2025:
Abstract #3011 – Monday April 28th, 2-5PM Experimental & Molecular Therapeutics, Poster section 20, Board 12 – “Novel CDK12 inhibitors with preclinical anti-tumor activity and best-in-class profile on HER2 low breast cancer patient samples” – Download PDF here
Abstract #4724, Tuesday April 29th, 9-12PM, Clinical Research, Poster section 34, Board 22 – “Evaluating immunotherapy and combination therapy efficacy in kidney cancer using a multicellular 3D immune-microtumor model” – Download PDF here
Abstract #3917 – Tuesday April 29th, 9-12PM, Tumour Biology, Poster section 4, Board 10 – “A functional precision medicine assay for immunotherapy and combination therapy testing in liver and pancreatic cancers (PEAR-PAL)” – Download PDF here
Or check out our precision medicine workflow poster – Download PDF here
Check out our poster at the San Antonio Breast Cancer Symposium 2024 to learn more about how Pear Bio is advancing precision oncology through our PEAR-TNBC clinical trial.
Our PEAR-TNBC trial preprint is here! Discover how our precision medicine platform is looking to predict pathological complete response in triple-negative breast cancer patients: https://doi.org/10.1101/2024.10.25.24314885
“Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial”
Peter Hall, Matthew Williams, Eleonora Peerani, Elli Tham, Francesco Iori, George Richard Tiger Bevan de Fraine, Kerrie Loughrey, Andreas Dimitri Kaffa, Thomas David Laurent Richardson, Carolina Liberal, Angeliki Velentza-Almpani, Demi Annemarie Wiskerke, Farah Sangkolah, Aston Martin Crawley, Jay Kearney, Nourdine Kabirou Bah, Marios Konstantinos Tasoulis, Cliona C Kirwan, Susan Cleator, Steve Chan, Duleek Ranatunga